<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394653</url>
  </required_header>
  <id_info>
    <org_study_id>060-CL-209</org_study_id>
    <nct_id>NCT01394653</nct_id>
  </id_info>
  <brief_title>A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake</brief_title>
  <official_title>Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion With Water -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare time-course changes of plasma concentration of YM060 orally-disintegrating
      tablet with those of conventional tablet. Tablets will be administered with water.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of YM060 plasma concentration -time curve</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal concentration of YM060 plasma concentration</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECG</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <condition>Plasma Concentration of YM060</condition>
  <arm_group>
    <arm_group_label>orally-disintegrating (OD) tablet precedence group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional tablet precedence group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM060</intervention_name>
    <description>oral, with water</description>
    <arm_group_label>orally-disintegrating (OD) tablet precedence group</arm_group_label>
    <arm_group_label>conventional tablet precedence group</arm_group_label>
    <other_name>ramosetron</other_name>
    <other_name>Irribow</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy assessed by the principal investigator or sub-investigators

          -  non-smoking or stop smoking at least 90 days before the study

          -  body weight: over 50.0kg and less than 80.0kg

          -  body mass index (BMI): over 17.6 and less than 26.4

        Exclusion Criteria:

          -  participated in another clinical trial (including a post-marketing clinical study)
             within 120 days before the study

          -  donated 400mL of whole blood within 90 days, 200mL of whole blood within 30 days or
             blood components within 14 days before the study

          -  received any drugs within 7 days before the study or going to receive any drugs

          -  deviance from normal range in vital signs (blood pressure, pulse rate, and body
             temperature) or 12-lead ECG

          -  deviance from normal range in lab-tests

          -  history of drug allergy

          -  history or current diagnosis of stomach, small intestine or large intestine diseases

          -  history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis
             ulcerative)

          -  history or current diagnosis of colitis ischemic

          -  history or current diagnosis of hepatic diseases

          -  history or current diagnosis of cardiovascular diseases

          -  history or current diagnosis of respiratory diseases

          -  history or current diagnosis of malignant tumor

          -  received ramosetron tablet
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YM060</keyword>
  <keyword>ramosetron</keyword>
  <keyword>orally-disintegrating tablet</keyword>
  <keyword>OD tablet</keyword>
  <keyword>bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

